Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology
Lumera Corporation has announced that it has extended its collaboration agreement with the Institute for Systems Biology (ISB).
The goal of the collaboration is to use Lumera’s ProteomicProcessor™ to identify biomarkers associated with drug toxicity and cancer.
As previously announced, ISB researchers have demonstrated a label-free assay to determine protein expression patterns using a panel of specific antibodies printed on Lumera’s NanoCapture-Gold™ microarray and analyzed on the company’s ProteomicProcessor ™ instrument system.
“We are quite pleased with the progress of the past year,” said Dr. Leroy Hood, President of the Institute for Systems Biology. “Lumera’s platform provides unique advantages in biomarker discovery and we are committed to moving the science forward.”
“Early results from ISB have been proof positive that our technology adds significant value to the biomarker discovery market. We feel that with a continued emphasis on this project, we will arrive at a very important publication and will establish methods by which others will be able to develop their own assays,” said Dr. Timothy Londergan, Lumera’s Bioscience Business Unit.
As previously discussed by the company, biomarkers are important indicators of disease and their identification can lead to the development of targeted drug solutions to prevent or arrest the disease.